Cilostamide
CAS 68550-75-4
Cilostamide (CAS 68550-75-4) is a Phase 2 pharmaceutical compound with 5 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | Potency | 15434.492307692306 nM | 34 | - |
| - | IC50 | 6066.91 nM | 24 | - |
| - | AC50 | 23802.862 nM | 5 | - |
| - | Ki | 5985.5 nM | 4 | - |
| - | EC50 | 4403.033333333334 nM | 3 | - |
IUPHAR Ligand-Target Data
Curated ligand-target interaction rows with action, affinity, and literature identifiers.
| Target | Action | Affinity | PubMed |
|---|---|---|---|
| phosphodiesterase 3A PDE3A |
Inhibition | 7.5 pIC50 | 10644042 |
| phosphodiesterase 3B PDE3B |
Inhibition | 7.3 pIC50 | 10644042 |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Cilostamide used for in pharmaceutical contexts?
Cilostamide (CAS 68550-75-4) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Cilostamide?
No adverse-event association or SIDER side-effect rows are rendered for Cilostamide in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Cilostamide also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Cilostamide with EU status "permitted".
What clinical phase is Cilostamide in?
Cilostamide is rendered with ChEMBL max phase 2.